ArticleHepatology international2026
NAT10 promotes the activation of hepatic stellate cells by modulating the TGF-β1-ac4C-COL1A1 axis.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated epigenetic networks in aging: from histone to RNA modifications.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLiver fibrosis is characterized by deposition of excessive extracellular matrix (ECM). The major source of ECM is activated hepatic stellate cells (HSCs). NAT10 is the only known acetyltransferase catalyzing ac4C RNA modification. The purpose of this study is to explore the role of NAT10 acting as ac4C acetyltransferase during HSC activation.
methodsNAT10 was detected in fibrotic liver tissues from S. japonicum infected mice with immunohistochemistry and TGF-β1 stimulated LX-2 human HSC cells with Western blot and immunofluorescent staining. NAT10 was inhibited with specific siRNA in LX-2 cells to detect HSC activation molecular marker with Western blot, cell motility with Transwell assay, cell proliferation with CCK8 assay. ac4C modification was assessed in TGF-β1 stimulated LX-2 cells with immunofluorescent staining. ac4C chemical sequencing and transcriptomic sequencing analysis were performed to analyze ac4C modified genes regulated by NAT10 in TGF-β1 stimulated LX-2 cells. Possible target genes regulated by NAT10 were determined using qPCR, RIP-qPCR, RNA stability assay, and were further verified using primary hepatic stellate cells from mice and using analysis of GEO datasets.
resultsNAT10 increases in S. japonicum infected mice liver and activated HSCs. NAT10 inhibition suppresses HSC activation. NAT10 is correlated with TGFB1 and COL1A1 expression in activated HSCs. NAT10 promotes the ac4C modification and stability of TGFB1 and COL1A1 mRNA, thus enhancing their protein expression.
conclusionsNAT10 functions as an ac4C acetyltransferase and forms a positive feedback with TGF-β1 in HSCs, thereby modulating the TGF-β1-ac4C-COL1A1 axis, to promote HSC activation and liver fibrosis progression.
Indexed as
Identifiers
41559481What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.